These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32678032)

  • 1. Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
    Bellat V; Verchère A; Ashe SA; Law B
    BMC Cancer; 2020 Jul; 20(1):661. PubMed ID: 32678032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
    Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
    Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor.
    Wu YS; Quan Y; Zhang DX; Liu DW; Zhang XZ
    Biol Pharm Bull; 2017; 40(10):1747-1753. PubMed ID: 28966246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer.
    Chiu CF; Lin YQ; Park JM; Chen YC; Hung SW; Chiu CC; Chang CF
    Biomed Pharmacother; 2020 Aug; 128():110309. PubMed ID: 32505820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.
    Wu Y; Zhang D; Wu B; Quan Y; Liu D; Li Y; Zhang X
    Chem Pharm Bull (Tokyo); 2017 Aug; 65(8):768-775. PubMed ID: 28539531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
    Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
    Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells.
    Niwa AM; D Epiro GF; Marques LA; Semprebon SC; Sartori D; Ribeiro LR; Mantovani MS
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):557-71. PubMed ID: 26932586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel resveratrol-salinomycin combination sensitizes ER-positive breast cancer cells to apoptosis.
    Venkatadri R; Iyer AKV; Kaushik V; Azad N
    Pharmacol Rep; 2017 Aug; 69(4):788-797. PubMed ID: 28605700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 13. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
    Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
    Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
    Corrales-Sánchez V; Noblejas-López MDM; Nieto-Jiménez C; Pérez-Peña J; Montero JC; Burgos M; Galán-Moya EM; Pandiella A; Ocaña A
    J Cell Mol Med; 2020 Mar; 24(5):3117-3127. PubMed ID: 32032474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.
    Koo KH; Kim H; Bae YK; Kim K; Park BK; Lee CH; Kim YN
    Cell Death Dis; 2013 Jun; 4(6):e693. PubMed ID: 23807222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells.
    Dewangan J; Tandon D; Srivastava S; Verma AK; Yapuri A; Rath SK
    Apoptosis; 2017 Oct; 22(10):1246-1259. PubMed ID: 28748373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.
    Angel CZ; Beattie S; Hanif EAM; Ryan MP; Guerra Liberal FDC; Zhang SD; Monteith S; Buckley NE; Parker E; Haynes S; McIntyre AJ; Haddock P; Sharifova M; Branco CM; Mullan PB
    Cell Commun Signal; 2024 Sep; 22(1):454. PubMed ID: 39327614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.